Showing posts with label pandemic influenza. Show all posts
Showing posts with label pandemic influenza. Show all posts

Sunday, August 16, 2026

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, August 16 '26)-

 


    Biochem Biophys Res Commun

  1. RAO RM, Kumar N, P SP, Rao MJ, et al
    Convergent genetic and structural parameters of cardiovascular disease related insights of post-acute COVID-19.
    Biochem Biophys Res Commun. 2026;831:154319.
    PubMed         Abstract available

  2. LIU C, Yan Z, Tao Z, Yang W, et al
    C5a-C5aR1 axis activation drives neutrophil extracellular trap formation in SARS-CoV-2 N protein-mediated acute kidney injury.
    Biochem Biophys Res Commun. 2026;831:154305.
    PubMed         Abstract available


    J Clin Microbiol

  3. AEBISCHER A, Gunther A, Piesche R, Wernike K, et al
    Development of a multi-species luciferase-based double-antigen ELISA for the detection of antibodies against influenza A virus H5 clade 2.3.4.4b.
    J Clin Microbiol. 2026 Aug 13:e0190725. doi: 10.1128/jcm.01907.
    PubMed         Abstract available


    J Gen Virol

  4. LOZANO-MONTALBA L, Denis Z, Courgnaud V, Moreno-Garcia J, et al
    Glycosphingolipids are essential entry factors for non-influenza orthomyxoviruses.
    J Gen Virol. 2026;107.
    PubMed         Abstract available


    J Immunol

  5. MCKERNAN KE, Cephus JY, Kuehnle SN, Henriquez-Pilier E, et al
    Deficiency in circulating T cells in four core genotypes mice with Sry translocation.
    J Immunol. 2026;215:vkag207.
    PubMed         Abstract available


    J Infect

  6. HANSEN CL, Shaikh N, Naeger S, Torcel-Pagnon L, et al
    Hospitalizations and deaths from major respiratory viruses in the US: An ensemble time series modeling study, 2016-2025.
    J Infect. 2026;93:106811.
    PubMed         Abstract available

  7. VINK E, Murphy ME, Gunson R, MacConnachie A, et al
    Respiratory viral detection in adult severe acute respiratory infection post-COVID-19 pandemic: implications for antimicrobial stewardship.
    J Infect. 2026;93:106805.
    PubMed         Abstract available

  8. RAN J, Zhu L, Ning M, Zhang W, et al
    Age-associated impairment of humoral and cellular immune responses to SARS-CoV-2 in a large community cohort with hybrid immunity.
    J Infect. 2026 Jul 1:106803. doi: 10.1016/j.jinf.2026.106803.
    PubMed         Abstract available

  9. KONG M, Gao HX, Song XD, Yang GJ, et al
    Convergent neutralizing antibodies to SARS-CoV-2 variants over 2.5 years after BA.5/BF.7 breakthrough infection.
    J Infect. 2026 Jun 18:106799. doi: 10.1016/j.jinf.2026.106799.
    PubMed         Abstract available

  10. ATUKORALE VN, Kwong JC, Hernandez A, Moineddin R, et al
    Factors associated with severe health outcomes among community-dwelling older adults hospitalized with respiratory syncytial virus.
    J Infect. 2026;93:106797.
    PubMed         Abstract available

  11. DONG S, Li M, Huo D, Zhao H, et al
    Impact of EV-A71 vaccination and non-pharmaceutical interventions on hand, foot, and mouth disease: A 14-year interrupted time series analysis.
    J Infect. 2026;93:106795.
    PubMed         Abstract available

  12. TRUONG T, Radin JM, Li L, Ordonez-Mena JM, et al
    Burden and economic impact of RSV hospitalisations among English adults, 2023/24.
    J Infect. 2026;93:106792.
    PubMed         Abstract available

  13. WANG X, Yin J, Xu B, Guanhua X, et al
    Clinical epidemiological characteristics of hospitalized pediatric Mycoplasma pneumoniae pneumonia in China.
    J Infect. 2026 Jun 10:106793. doi: 10.1016/j.jinf.2026.106793.
    PubMed         Abstract available


    J Virol

  14. PULIT-PENALOZA J, Belser JA, Brock N, Kieran TJ, et al
    Risk assessment of avian influenza A(H5N5) virus from the first human case using the ferret model.
    J Virol. 2026 Aug 11:e0085626. doi: 10.1128/jvi.00856.
    PubMed         Abstract available


    N Engl J Med

  15. LIU Z, Zhang L, Jiang M
    Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults.
    N Engl J Med. 2026;395:724.
    PubMed        

  16. LOCQUET M, Dogne JM
    Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults.
    N Engl J Med. 2026;395:724-725.
    PubMed        

  17. HUANG G, Das R, Wilson E
    Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults. Reply.
    N Engl J Med. 2026;395:725-726.
    PubMed        


    Pediatrics


  18. Recommendations for Prevention and Control of Influenza in Children, 2026-2027: Policy Statement.
    Pediatrics. 2026 Aug 10. doi: 10.1542/peds.2026-078778.
    PubMed         Abstract available


  19. Recommendations for Prevention and Control of Influenza in Children, 2026-2027: Technical Report.
    Pediatrics. 2026 Aug 10. doi: 10.1542/peds.2026-078779.
    PubMed         Abstract available


    PLoS Comput Biol

  20. FORNA A, Damodaran L, Gunning CE, Rahimi P, et al
    Alignment-free prediction of cross-reactivity in influenza A (H3N2) anticipates antigenic drift.
    PLoS Comput Biol. 2026;22:e1014628.
    PubMed         Abstract available


    PLoS One

  21. MURPHY C, Cheng SMS, Mak L, So HC, et al
    Diagnostic agreement between Rhinoswabs and joint nose and throat swabs for the detection of influenza and SARS-CoV-2 among symptomatic ambulatory patients in Hong Kong.
    PLoS One. 2026;21:e0355869.
    PubMed         Abstract available

  22. KILDAY D, Korvink M, Tatum D, Cao Z, et al
    Association between COVID-19 by variant period and delivery-related outcomes in the United States.
    PLoS One. 2026;21:e0355223.
    PubMed         Abstract available

  23. TAMAKI S, Kawashima R, Uematsu T, Kawakami F, et al
    Eosinophil-associated intestinal immune responses following SARS-CoV-2 infection in K18-hACE2 mice.
    PLoS One. 2026;21:e0355607.
    PubMed         Abstract available

  24. PIETAN L, Phillippi E, Melo M, El-Shanti H, et al
    Genome-wide machine learning analysis of anosmia and ageusia with COVID-19.
    PLoS One. 2026;21:e0355832.
    PubMed         Abstract available

  25. CHEN PY, Dang LH, Hung SH
    The association between meteorological factors and influenza incidence in Taiwan: Regional heterogeneity and subtropical climate variability.
    PLoS One. 2026;21:e0355559.
    PubMed         Abstract available

  26. PARK S, Kwon JA, Kim HS, Choi Y, et al
    Socioeconomic differences in influenza vaccination coverage by government financial support status: A population-based study in Korea.
    PLoS One. 2026;21:e0353764.
    PubMed         Abstract available

  27. ALSHAHRANI A, Reddy RS, Gular K, Kakaraparthi VN, et al
    Postural control and trunk mobility impairments in adults with long COVID: A cross-sectional study using computerized posturography and clinical biomechanical tools.
    PLoS One. 2026;21:e0354593.
    PubMed         Abstract available

  28. TUT G, Lancaster T, Sylla P, Bone D, et al
    High rates of SARS-CoV-2 reinfection in residents of long term care facilities despite robust spike-specific immunity following serial vaccination.
    PLoS One. 2026;21:e0354079.
    PubMed         Abstract available

  29. KIM Y, Lee J, Park J
    Concentration of hospital utilization in the capital area among elderly inpatients from non-capital regions in South Korea: Before and during the COVID-19 pandemic.
    PLoS One. 2026;21:e0336744.
    PubMed         Abstract available

  30. FREIRE SF, Shimizu IS, Lima CAS, Adhikari NKJ, et al
    The association between resource availability and knowledge, attitudes, and practice about protective ventilation among ICU directors - A nationwide cross-sectional survey.
    PLoS One. 2026;21:e0355354.
    PubMed         Abstract available

  31. KARADUMAN E, Toprak N, Cevik A, Erail S, et al
    Factors associated with fear and coping strategies during pandemic in female university students: The moderator role of physical activity and infection status.
    PLoS One. 2026;21:e0355544.
    PubMed         Abstract available

  32. IRIEMENAM NC, Osawe S, Akanbi OA, Akinmulero O, et al
    High prevalence of SARS-CoV-2 antibodies among frontline healthcare workers during the COVID-19 pandemic in three states of Nigeria from August to December 2022.
    PLoS One. 2026;21:e0354606.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  33. DIAZ TOVAR JS, Dos Reis FP, Moriyama LT, Pego-Fernandes PM, et al
    Anatomy-resolved digital twin framework for personalized light dosimetry in lung therapies.
    Proc Natl Acad Sci U S A. 2026;123:e2612370123.
    PubMed         Abstract available


    Vaccine

  34. GEBREMARIAM AG, Genie M, Le H, Regan A, et al
    Vaccine uptake in the context of mandate announcement and removal: Evidence from Europe and North America.
    Vaccine. 2026;88:128825.
    PubMed         Abstract available

  35. FAVRE G, Pfund A, Gerbier E, Anselem O, et al
    Acceptability and preferences regarding RSV immunisation during pregnancy: a cross-sectional study in diverse global settings.
    Vaccine. 2026;88:128783.
    PubMed         Abstract available

  36. CARAZO S, Skowronski DM, Sauvageau C, Talbot D, et al
    2024/25 end-of-season KP.2 vaccine effectiveness against COVID-19 hospitalization in older adults: a test-negative study in Quebec, Canada.
    Vaccine. 2026;88:128786.
    PubMed         Abstract available

  37. EBRAHIMI N, de Whalley P, Kanji N, Ramasamy MN, et al
    ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses.
    Vaccine. 2026;88:128951.
    PubMed         Abstract available

  38. DALEXIS RD, Beogo I, Xu Y, Muray M, et al
    Post-COVID-19 pandemic inequities in routine childhood immunization in Canada: racial disparities in uptake of polio, meningococcal conjugate, and varicella vaccines.
    Vaccine. 2026;88:128931.
    PubMed         Abstract available

  39. HUSSAIN HS, Yousafzai MT, Iqbal J, Aslam ZM, et al
    Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: A non-inferiority, randomized, double-blind, phase IV clinical trial in Pakistan.
    Vaccine. 2026;88:128918.
    PubMed         Abstract available

  40. YOON SK, Phillips AL, Battan-Wraith S, Thiese MS, et al
    Real-world effectiveness and safety of protein-based and mRNA COVID-19 vaccines (BEEHIVE trial).
    Vaccine. 2026;88:128954.
    PubMed         Abstract available

  41. DIARRA M, Li S, Gaur S, Greenberg P, et al
    Understanding parent motivation for participating in the Pfizer COVID-19 vaccine trial.
    Vaccine. 2026;88:128960.
    PubMed         Abstract available

  42. BELL S, Chantler T, Passanante A, Pryce J, et al
    Maternal respiratory syncytial virus (RSV) vaccine perceptions amongst pregnant women and mothers of infants and toddlers in England: a qualitative study.
    Vaccine. 2026;88:128955.
    PubMed         Abstract available

  43. MAEDA H, Igarashi A, Mitsui S, Suzuki K, et al
    Interim analysis of effectiveness of JN.1-adapted conventional and self-amplifying mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infection in adults aged >/=60 years, Japan, October 2024-April 2025.
    Vaccine. 2026;88:128964.
    PubMed         Abstract available

  44. BARASA L, Onyango G
    The institutional roots of vaccine uptake and hesitancy: evidence from Africa.
    Vaccine. 2026;88:128980.
    PubMed         Abstract available

  45. LI J, Wang Z, Gong Y
    Country-level immunization recovery and DTP1 no-dose proxy burden after COVID-19: a descriptive ecological analysis of WUENIC, 2010-2024.
    Vaccine. 2026;88:128973.
    PubMed         Abstract available

  46. KIM T, Wang X, Rajtmajer S, Harden JJ, et al
    Elected officials' online anti-vaccination statements respond to online engagement.
    Vaccine. 2026;88:128901.
    PubMed         Abstract available

  47. C M, Dymock M, Flanagan KL, Plebanski M, et al
    The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults.
    Vaccine. 2026;88:128970.
    PubMed         Abstract available

  48. DE PADUA MC, Antunes MOB, Stein RT, Pinto LA, et al
    Effectiveness of BNT162B2 and CoronaVac vaccines in reducing COVID-19 severity among children aged 3-4 years in Brazil.
    Vaccine. 2026;88:128974.
    PubMed         Abstract available

  49. TAY CJX, Koh CWT, Ooi JSG, Li HE, et al
    Over-induction of innate immune responses suppresses T cell response to mRNA SARS-CoV-2 vaccination.
    Vaccine. 2026;88:128983.
    PubMed         Abstract available

  50. RAFIZADEH A, Wijekoon D, Aung ET, Aguirre I, et al
    Influenza vaccination uptake among people living with HIV in Melbourne, 2015-2025: a repeated cross-sectional study.
    Vaccine. 2026;90:129038.
    PubMed         Abstract available

  51. SAITOH A, Takaku M
    Partner awareness and support for maternal RSV vaccination: a paired survey of pregnant women and co-residing partners in Japan.
    Vaccine. 2026;88:128946.
    PubMed         Abstract available

  52. PAUL KK, Newall AT
    The cost of respiratory syncytial virus (RSV) across all ages to the Australian healthcare system.
    Vaccine. 2026;88:128922.
    PubMed         Abstract available

  53. AUNG TN, Muyindike W, Hoeppner SS, Nanfuka V, et al
    COVID-19 vaccination among people with HIV in Uganda: lessons from a high-risk group with high vaccine uptake for the next pandemic.
    Vaccine. 2026;88:128912.
    PubMed         Abstract available

  54. HENSLEY AA, Jiles KA, Edwards S, Clinchard C, et al
    Characteristics of successful and unsuccessful strategies to increase vaccine intention and improve vaccine uptake for U.S. adult populations in the Affordable Care Act era (2010-2025): a systematic review and meta-regression.
    Vaccine. 2026;88:128910.
    PubMed         Abstract available

  55. MCCONEGHY KW, Wilker EH, DeVone F, Skov B, et al
    Vaccine effectiveness of mRNA-1345 against RSV-associated hospitalization and medically attended acute respiratory illness among US veterans, 2025-2026.
    Vaccine. 2026;88:128882.
    PubMed         Abstract available

  56. NAKANO T, Iwata S, Oishi K, Iguchi E, et al
    Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.
    Vaccine. 2026;88:128871.
    PubMed         Abstract available

  57. MALTEZOU HC, Borg M, Botelho-Nevers E, Brantsaeter AB, et al
    Vaccination policies for healthcare personnel in Europe, 2026.
    Vaccine. 2026;88:128839.
    PubMed         Abstract available

  58. MYERS TR, Zauche LH, Marquez PL, McCullum I, et al
    V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023.
    Vaccine. 2026;88:128725.
    PubMed         Abstract available

  59. PRAT-AYMERICH C, Yeghiazaryan L, Pathirana RD, Gautier V, et al
    A prematurely terminated phase 2, randomised trial to evaluate immunogenicity and reactogenicity of a single versus two-dose primary vaccination regimen of the mRNA vaccine BNT162b2 in previously SARS-CoV-2 infected children 5-11 years old (CoVacc tri
    Vaccine. 2026;88:128769.
    PubMed         Abstract available

  60. SINGER D, La EM, Dubois de Gennes C, Graham J, et al
    Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18-49 years at increased risk for severe RSV disease.
    Vaccine. 2026;88:128770.
    PubMed         Abstract available

  61. GONDWE KW, Hearst MO, Mbutuka HR, Khwepeya M, et al
    Factors associated with COVID-19 vaccine acceptance among refugee women at Dzaleka refugee camp in Malawi.
    Vaccine. 2026;88:128862.
    PubMed         Abstract available

  62. LIU Z, Wang X, Hu Y, Duan X, et al
    Burden of infection and hospitalization from respiratory syncytial virus-associated acute lower respiratory tract infections in Chinese children: Modeling of national, regional, and provincial estimates.
    Vaccine. 2026;88:128875.
    PubMed         Abstract available

  63. MORIO R, Takazono T, Morimoto S, Ashizawa N, et al
    Comparison of immunogenicity of mRNA and protein subunit SARS-CoV-2 vaccines in dialysis patients: a multicenter study.
    Vaccine. 2026;88:128861.
    PubMed         Abstract available

  64. TORKAMAN-ASADI F, Bakhtiari S, Safarzadeh M, Riahi-Rad Z, et al
    Clinical outcomes among SARS-CoV-2 omicron-infected adults according to prior infection and vaccination history in Iran: A retrospective registry-based study.
    Vaccine. 2026;88:128868.
    PubMed         Abstract available

  65. FLEMING JA, Colistro V, Knudson S, Colomar M, et al
    Timing and frequency of antenatal care visits in relation to maternal respiratory syncytial virus vaccine opportunities in four Latin American countries.
    Vaccine. 2026;88:128854.
    PubMed         Abstract available

  66. ASAGA PM, Kroeger A, Yako A, Makpo J, et al
    Global misinformation, local consequences: conspiracy theory endorsement and a graded association with COVID-19 vaccine refusal across Nigeria.
    Vaccine. 2026;88:128827.
    PubMed         Abstract available

  67. RICKE IJ, Ward C, Spaulding AB, Sherwood NE, et al
    Caregiver COVID-19 vaccine status and its influence on pediatric vaccination decisions in a US cohort.
    Vaccine. 2026;88:128847.
    PubMed         Abstract available

  68. RAZZAGHI H, Garacci E, Kahn KE, Meghani M, et al
    Maternal and infant immunizations for respiratory diseases, United States, may 2025.
    Vaccine. 2026;88:128823.
    PubMed         Abstract available


    Virology

  69. BYRNE AMP, James J, Thomas SS, Warren CJ, et al
    Impact of prior low-pathogenicity avian influenza H7N7 exposure on susceptibility and protection against homologous high-pathogenicity avian influenza H7N7 challenge in chickens.
    Virology. 2026;624:111047.
    PubMed         Abstract available

Sunday, August 9, 2026

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, August 9 '26)

 


    Ann Intern Med

  1. CHEN V, Glatt AE
    In older adults, mRNA-1010 vs. a licensed standard-dose influenza vaccine reduced influenza A- or B-related ILI at a median 181 d.
    Ann Intern Med. 2026 Aug 4. doi: 10.7326/ANNALS-26-02527.
    PubMed         Abstract available


    Antimicrob Agents Chemother

  2. SUN Z, Huang Y, Guo R, Jiang T, et al
    Anti-RSV drug screening and inhibition of RSV infection by lapatinib through the IL-17 pathway.
    Antimicrob Agents Chemother. 2026;70:e0197225.
    PubMed         Abstract available

  3. RODRIGUEZ L, Andreatta K, Chen S, Hu Y, et al
    Virologic insights from the phase 3 REDPINE trial: remdesivir in renally impaired and immunocompromised patients with COVID-19.
    Antimicrob Agents Chemother. 2026;70:e0191225.
    PubMed         Abstract available


    Antiviral Res

  4. WANG K, Gibbons JS, Bisht N, Reyes AC, et al
    SARS-CoV-2 resistance pathways to EDP-235.
    Antiviral Res. 2026;253:106493.
    PubMed         Abstract available

  5. WU R, Wang H, Yin R, Gemingnuer A, et al
    Nanoparticles in viral pneumonia: diagnosis, therapy, and prevention.
    Antiviral Res. 2026;253:106482.
    PubMed         Abstract available


    BMC Pediatr

  6. CHEN H, Fan Y, Huang Y
    Epidemiological characteristics and seasonal dynamics of six respiratory pathogens in children: a 2-year retrospective cross-sectional study in Chengdu, China.
    BMC Pediatr. 2026;26:718.
    PubMed         Abstract available

  7. AMPOFO K, Heller E, Platt-Koch A, Gesteland P, et al
    Burden of laboratory-confirmed RSV hospitalization in children <5 years-of-age; 2019-2022.
    BMC Pediatr. 2026;26:706.
    PubMed         Abstract available


    J Immunol

  8. ACKLAND J, Barozi V, Penrice-Randal R, Hartley C, et al
    Identifying molecular signatures underpinning treatment responses to novel therapeutics influencing COVID-19 outcomes.
    J Immunol. 2026;215:vkag189.
    PubMed         Abstract available

  9. SILVA JDC, Almeida C, Silva BMS, Bonfim BS, et al
    Elastase and myeloperoxidase participate in neutrophil extracellular trap release stimulated by SARS-CoV-2.
    J Immunol. 2026;215:vkaf313.
    PubMed         Abstract available


    J Infect Dis

  10. SMITH D, Weir IR, Ramirez S, Coelho CH, et al
    Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses.
    J Infect Dis. 2026 Feb 17:jiag091. doi: 10.1093.
    PubMed         Abstract available

  11. PLATT AP, Callier V, Grazioli A, Hu Z, et al
    Association of Plasma Biomarkers of Immunothrombosis With Death in Patients With Coronavirus Disease 2019 on Extracorporeal Membrane Oxygenation.
    J Infect Dis. 2026;234:e40-e53.
    PubMed         Abstract available

  12. SANGIORGIO G, Chamberlin G, Castagnoli R, Wachter B, et al
    Immune-Based Cytokine Signatures of Prolonged Pandemic-Associated Chilblains.
    J Infect Dis. 2026;234:e29-e33.
    PubMed         Abstract available

  13. JAYAWARDENA I, Dean NE, Witrick B, Litwin AH, et al
    2024-2025 COVID-19 mRNA Vaccine Effectiveness against Severe Disease.
    J Infect Dis. 2026 Mar 2:jiag137. doi: 10.1093.
    PubMed         Abstract available

  14. ROSAS-SALAZAR C, Gebretsadik T, Chappell JD, Peebles RS Jr, et al
    Infant Infection With Respiratory Syncytial Virus Genotypes and Subsequent Childhood Asthma Risk.
    J Infect Dis. 2026;234:e34-e39.
    PubMed         Abstract available

  15. KACHIKIS A, Frivold C, Pike M, Reed JC, et al
    Comparison of Respiratory Syncytial Virus (RSV)-Specific Antibody Durability in Pregnant/Postpartum Individuals and Older Adults After RSV Vaccination.
    J Infect Dis. 2026 Mar 26:jiag111. doi: 10.1093.
    PubMed         Abstract available

  16. KOBERSSY Z, Daher J, Durieux JC, Atieh O, et al
    Comparison of Immune Activation and Gut Barrier Dysfunction between Long COVID and HIV infection.
    J Infect Dis. 2026 Mar 31:jiag146. doi: 10.1093.
    PubMed         Abstract available

  17. FEYS S, Heylen J, Goncalves SM, Pereira I, et al
    Genetic variation in the long pentraxin PTX3 and Dectin-1 does not predispose to influenza- or COVID-19-associated pulmonary aspergillosis.
    J Infect Dis. 2026 Aug 7:jiag403. doi: 10.1093.
    PubMed         Abstract available


    PLoS One

  18. ALSHAMMARI AO, Alshammari HO, Ali H, Himmat B, et al
    A flexible exponential type family for modeling non-monotonic hazard rates with application to mortality analysis: A COVID-19 case study.
    PLoS One. 2026;21:e0331050.
    PubMed         Abstract available

  19. GOURAUD C, Guemouni S, Thoreux P, Ouazana-Vedrines C, et al
    Health-related quality of life among patients with long COVID according to the presence of a diagnosis of functional somatic disorder: A cross-sectional study.
    PLoS One. 2026;21:e0354238.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  20. ZHOU J, Li W, Wang X, Sun J, et al
    A structural and mechanistic atlas of NTD antibody neutralization and immune escape across SARS-CoV-2 prototype and its (sub-)variants.
    Proc Natl Acad Sci U S A. 2026;123:e2535385123.
    PubMed         Abstract available

  21. MULLER L, Sartori F, Dehning J, Eggl MF, et al
    Optimizing infectious disease mitigation under dynamic conditions.
    Proc Natl Acad Sci U S A. 2026;123:e2527395123.
    PubMed         Abstract available


    Vaccine

  22. XU N, Wang L, Zhao C, Shen Y, et al
    Advances in clinical immunogenicity evaluation of influenza vaccines.
    Vaccine. 2026;89:128989.
    PubMed         Abstract available

Saturday, August 1, 2026

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, August 1 '26)

 


    Arch Virol

  1. LEE K, An SH, Heo GB, Lee YJ, et al
    Genomic characterization of H6N1 avian influenza viruses from wild birds and domestic ducks in the republic of Korea and Mongolia (2022-2024).
    Arch Virol. 2026;171:238.
    PubMed         Abstract available


    Biochem Soc Trans

  2. MADDUMAGE JC, Dow GR, Murdolo LD, Liwei Leong S, et al
    Deciphering influenza B virus-derived peptides and their presentation by HLA class I molecules.
    Biochem Soc Trans. 2026;54:1021-1052.
    PubMed         Abstract available


    BMC Pediatr

  3. IBRAHIM HM, Mansour MGE, Zaitoun R, Rushdy M, et al
    HLA-B class I allele associations with neurological complications in pediatric SARS-CoV-2 infection: a retrospective observational study.
    BMC Pediatr. 2026;26:691.
    PubMed         Abstract available


    Epidemiol Infect

  4. NAQVI OH, Wendelboe AM, Beasley WH, Tyungu DL, et al
    Epidemiological characteristics of paediatric COVID-19 and influenza co-infections in the United States, 2020-2024.
    Epidemiol Infect. 2026;154:e105.
    PubMed         Abstract available


    J Immunol

  5. CHEUNG MW, Choi JD, Stempak JM, Chandran V, et al
    T cell immunity to SARS-CoV-2 vaccination in inflammatory bowel disease patients treated with anti-cytokine biologics.
    J Immunol. 2026;215:vkag173.
    PubMed         Abstract available

  6. NELSON SA, Rattan A, Marathe B, White CL, et al
    Distinct kinetic features of innate and adaptive responses in influenza A versus influenza B-infected mice.
    J Immunol. 2026;215:vkag196.
    PubMed         Abstract available


    J Infect

  7. SANZ-MUNOZ I, Ciria-Gil CJ, Hernandez M, Santiago C, et al
    Pre-existing and Cross-Reactive Immunity to Avian Influenza H5N1 in Humans: Implications for Pandemic Risk and Vaccine Strategies.
    J Infect. 2026 Jul 30:106822. doi: 10.1016/j.jinf.2026.106822.
    PubMed         Abstract available


    J Virol

  8. MCCAFFREY KD, Esfahani BG, Elbehairy MA, McCormick AL, et al
    Molecular basis for protection and cross-protection by human antibodies targeting the parainfluenza virus hemagglutinin-neuraminidase protein.
    J Virol. 2026 Jul 31:e0050226. doi: 10.1128/jvi.00502.
    PubMed         Abstract available

  9. CHEN X, Yan J, Li M, Liu H, et al
    c-Fos enhances influenza virus replication by stabilizing the M2 protein and promoting autophagosome accumulation.
    J Virol. 2026 Jul 27:e0091626. doi: 10.1128/jvi.00916.
    PubMed         Abstract available


    JAMA

  10. BAUDIN F, Pouyau R, Subtil F, Jarrasse C, et al
    Prone Positioning in Infants With Acute Bronchiolitis: The PROPOSITIS Randomized Clinical Trial.
    JAMA. 2026;336:315-322.
    PubMed         Abstract available


    Pediatrics

  11. YI Y, Edwards F, Wakefield S, Wildeman C, et al
    Child Welfare System Involvement in the United States: 2016-2023.
    Pediatrics. 2026;158:e2025074635.
    PubMed         Abstract available

  12. MORENO-PEREZ D, Catalan-Fernandez E, Croche-Santander B, Rios-Hurtado JM, et al
    Nirsevimab and Hospitalization for Lower Respiratory Tract Infection During the Second Season.
    Pediatrics. 2026;158:e2025075562.
    PubMed         Abstract available


    PLoS Comput Biol

  13. XU R, Ghaffarzadegan N, Zhang G, Aoki G, et al
    Population-level behavioral and structural drivers of COVID-19 vaccine uptake in the US.
    PLoS Comput Biol. 2026;22:e1013988.
    PubMed         Abstract available

  14. BEAULIEU M, Hoze N, Vieillefond V, Goetschy T, et al
    Quantitative analysis of massive SARS-CoV-2 testing in the community in France in 2021-2022 reveals the associations of variant, vaccination, and age with viral dynamics in symptomatic individuals.
    PLoS Comput Biol. 2026;22:e1013811.
    PubMed         Abstract available


    PLoS One

  15. ZHU K, Barberio J, Tsao N, Mor A, et al
    Trends in the incidence of asthma, atopic dermatitis, and multiple sclerosis before, during, and after the COVID-19 pandemic in a US claims database.
    PLoS One. 2026;21:e0355103.
    PubMed         Abstract available

  16. BRANNON GE, Chatterjee K, Jang CY, Markham Shaw C, et al
    Perceptions of Spanish-language COVID-19 video messaging among the Hispanic community: A qualitative study in the United States of America.
    PLoS One. 2026;21:e0339634.
    PubMed         Abstract available

  17. NELSON AK, Everett M, Smith R, Rogers L, et al
    Death by incarceration: Detention duration, overdose, and COVID-19 in Los Angeles County Jails, 2008-2023.
    PLoS One. 2026;21:e0351332.
    PubMed         Abstract available

  18. CASTRO MONTEIRO F, Luiza C Wuillaume M, Linhares Veloso Filho C, Figueiredo K, et al
    Identifying cluster profiles based on barriers and facilitators to physical activity during COVID-19 confinement: A cross-sectional study using machine learning analysis.
    PLoS One. 2026;21:e0354036.
    PubMed         Abstract available

  19. SUN L, Jiang Z, Chen Y, Han M, et al
    Exploring the mechanism of Shuangyu Granule in regulating immune-inflammatory responses in influenza through UPLC-Orbitrap-MS/MS, GC-MS, and network target analysis.
    PLoS One. 2026;21:e0353259.
    PubMed         Abstract available

  20. ROY SS, Nguyen NT, Zuniga A, Sarhaddi F, et al
    Mission imputable: Effects of missing data processing on infectious disease detection and prognosis.
    PLoS One. 2026;21:e0320105.
    PubMed         Abstract available

  21. ABUSKA D, Dikme O, Dikme O, Yurttas TT, et al
    Age-stratified prognostic performance of hematologic inflammatory indices for 30-day mortality in emergency department patients with PCR-confirmed COVID-19: A cohort study from the pre-vaccination pandemic era.
    PLoS One. 2026;21:e0354809.
    PubMed         Abstract available

  22. CALLAGHAN CW
    Cultural tightness and scientific capacity: A cross-national study of their synergistic and conflicting roles in COVID-19 pandemic outcomes.
    PLoS One. 2026;21:e0330983.
    PubMed         Abstract available

  23. KEBEDE M, Kusheta G, Jemal M, Abdurehman K, et al
    Determinants of parental traditional medicine use for children during COVID-19 in Dire Dawa city administration, Eastern Ethiopia, 2023/24: Mixed community based cross-sectional study design.
    PLoS One. 2026;21:e0354889.
    PubMed         Abstract available

  24. LIM MS, Park C, Lee E, Ko SY, et al
    A multiplex dual-probe RT-LAMP assay for rapid subtype-specific detection of respiratory syncytial virus A and B.
    PLoS One. 2026;21:e0354914.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  25. HAN AX, Hulme KD, Russell CA
    The global demand and potential public health impact of oral antiviral treatment stockpile for influenza pandemics.
    Proc Natl Acad Sci U S A. 2026;123:e2524161123.
    PubMed         Abstract available

  26. GERVAIS A, Marchal A, Maillard A, Le Voyer T, et al
    High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies.
    Proc Natl Acad Sci U S A. 2026;123:e2518581123.
    PubMed         Abstract available


    Vaccine

  27. LIU B, Li F, Yang Y, Tu H, et al
    In-depth monitoring of host cell proteins in influenza vaccines throughout multi-step purification processes.
    Vaccine. 2026;88:128957.
    PubMed         Abstract available

  28. KOSTANYAN L, Fukase H, Rumyantsev A, Hashizume K, et al
    Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged >/=50 years in Japan.
    Vaccine. 2026;88:128961.
    PubMed         Abstract available

  29. WEI Z, Feng X, Sun Q, Chen D, et al
    Factors affecting parental practices and attitudes toward influenza vaccination for children in China.
    Vaccine. 2026;88:128988.
    PubMed         Abstract available

Thursday, July 30, 2026

Estimating the #infection #fatality #ratio of zoonotic avian #influenza viruses with #pandemic potential using an evolutionary epidemiological model

 


Abstract

The risk of zoonotic avian influenza (AIV) infection to humans is challenging to estimate as many human avian influenza virus infections are undetected because infections may be asymptomatic, symptomatic but not tested, and difficult to identify through contact tracing, as human-to-human transmission is rare. We derive equations that consider the evolutionary mechanisms that give rise to pandemics and are parameterized to be consistent with records of past pandemics. We estimate that thousands of human infections with AIVs possessing pandemic potential occur worldwide in an average year. Combining these estimates with H5N1 fatality data, we estimate a historical average infection fatality ratio of 32 (95% uncertainty interval: 9.6-75) deaths per 10,000 infections. This estimate is comparable to SARS-CoV-2 during the recent pandemic and higher than seasonal human influenza. We estimate that preventing animal-to-human influenza spillovers would delay pandemic emergence by several years. Preventing human infections with AIVs is necessary given the high risk of severe outcomes to individuals and to reduce the risk of pandemics occurring in the future.


Competing Interest Statement

The authors have declared no competing interest.

Source: 


Link: https://www.medrxiv.org/content/10.64898/2026.01.21.26344526v3

____

Saturday, July 25, 2026

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, July 25 '26)

 


    Ann Intern Med

  1. JOHNSON D, Quinn S, Algase LF, Watkins C Jr, et al
    Telemedicine Policy and Practice: A Position Paper From the American College of Physicians.
    Ann Intern Med. 2026 May 12. doi: 10.7326/ANNALS-25-04194.
    PubMed         Abstract available


    BMC Pediatr

  2. KHALILIAN MR, Goudarzi A, Karimi A, Fahimzad A, et al
    Echocardiographic assessment of cardiac involvement in pediatric COVID-19 patients: a cross-sectional study.
    BMC Pediatr. 2026;26:677.
    PubMed         Abstract available


    J Clin Microbiol

  3. LUUKINEN B, Lang M, Peltola M, Soinila A, et al
    From triplex to tetraplex: evaluation of the diagnostic accuracy of the new Roche Cobas Liat SARS-CoV-2, influenza A/B & RSV assay.
    J Clin Microbiol. 2026 Jul 20:e0027426. doi: 10.1128/jcm.00274.
    PubMed         Abstract available


    J Infect Dis

  4. ZHOU W
    Repeated Influenza Vaccination in Children: Effect Scale, Timing, and Causal Interpretation.
    J Infect Dis. 2026 Jul 24:jiag386. doi: 10.1093.
    PubMed        


    J Virol

  5. FAN M, Liu Z, Deng L, Zheng Y, et al
    LncRNA ckATP1A1-AS1 inhibits influenza A virus replication by mediating innate immune responses and suppressing viral nuclear import.
    J Virol. 2026 Jul 24:e0025926. doi: 10.1128/jvi.00259.
    PubMed         Abstract available

  6. ADENUGBA AR, Bohn P, Yu J, Fehrholz M, et al
    Sequence heterogeneity in pneumonia virus of mice reveals G gene-dependent modulation of virulence.
    J Virol. 2026;100:e0010326.
    PubMed         Abstract available

  7. MURRAY A, Nagaraj D, Schultz EM, Aloisio G, et al
    RSV can infect the human nasal epithelium via the basolateral route and shows distinct subgroup infectivity and basal cell tropism.
    J Virol. 2026;100:e0037426.
    PubMed         Abstract available

  8. AO Z, Vendramelli R, Buyu M, Truong T, et al
    A VSV-vector vaccine simultaneously targeting H5N1 hemagglutinin and matrix protein 2 induces robust neutralizing and ADCC antibody responses and provides full protection against lethal H5N1 infection in a mouse model.
    J Virol. 2026 Jun 16:e0009726. doi: 10.1128/jvi.00097.
    PubMed         Abstract available

  9. ZHANG Q, Xin J, Wang C, Zhang X, et al
    Cleavage of TOM1 by the SARS-CoV-2 main protease NSP5 prevents autophagic degradation of viral envelope.
    J Virol. 2026 Jun 12:e0043426. doi: 10.1128/jvi.00434.
    PubMed         Abstract available

  10. GIL-REDONDO JC, Riomoros-Barahona V, Valiente L, Valbuena A, et al
    Different mechanisms for human rhinovirus survival in the presence of deleterious amino acid substitutions at virion protein-protein or RNA-protein interfaces.
    J Virol. 2026;100:e0051126.
    PubMed         Abstract available

  11. WILT I, Jolley AA, Rahman K, Lai KK, et al
    IFITM1 and IFITM3 cooperate to restrict virus entry in endolysosomes.
    J Virol. 2026;100:e0067726.
    PubMed         Abstract available

  12. VARGAS DA, Albornoz LL, Pena-Morales M, Ortiz Rojas HJ, et al
    Within-host SARS-CoV-2 diversity in immunocompromised patients during acute infection.
    J Virol. 2026 Jun 9:e0222425. doi: 10.1128/jvi.02224.
    PubMed         Abstract available

  13. YU H-M, Zhu M-L, Zhao Y-L, Tan J-X, et al
    Research progress on the association between viruses and cardiac diseases.
    J Virol. 2026 Jun 9:e0038326. doi: 10.1128/jvi.00383.
    PubMed         Abstract available


    J Virol Methods

  14. HSIEH YH, Su CC, Lee CC, Chen PL, et al
    Analytical characteristics of the NeuMoDx SARS-CoV-2 assay and clinical agreement with the BD MAX system.
    J Virol Methods. 2026;345:115431.
    PubMed         Abstract available

  15. WANG B, Wang J, Sun Z, Sun G, et al
    Epidemiological characteristics of respiratory syncytial virus in children during 2021-2024.
    J Virol Methods. 2026;345:115433.
    PubMed         Abstract available


    Pediatrics

  16. KAO CM, Bahakel H, Heald-Sargent TA, Minniear TD, et al
    Influenza, COVID-19, and RSV Vaccinations for Immunocompromised Children and Household Contacts.
    Pediatrics. 2026 Jul 23:e2026075971. doi: 10.1542/peds.2026-075971.
    PubMed         Abstract available


    PLoS Genet

  17. WEYKOPF G, Bickmore WA, Biddie SC, Friman ET, et al
    Identifying severe COVID-19 risk variants modulating enhancer reporter activity in lung cells.
    PLoS Genet. 2026;22:e1012222.
    PubMed         Abstract available


    PLoS Med

  18. LI W, Yang W, Liu Y, Yao Y, et al
    Assessing spatial transmission risk of respiratory infectious diseases across cities of different socioeconomic tiers in China: A modelling study.
    PLoS Med. 2026;23:e1005172.
    PubMed         Abstract available

  19. GRAIS RF
    Whose fears count? Legitimacy, trust and viral outbreak responses after COVID-19.
    PLoS Med. 2026;23:e1005184.
    PubMed         Abstract available


    PLoS One

  20. CHURCHILL BF, Gao XS, Rong R
    Partisan differences in healthcare decision-making: Evidence from a vaccine experiment.
    PLoS One. 2026;21:e0352319.
    PubMed         Abstract available

  21. SCHEPISI C, Ventura M, Di Napoli A, Aragona M, et al
    The effect of COVID-19 and socioeconomic inequalities on emergency department accesses for psychiatric conditions.
    PLoS One. 2026;21:e0324305.
    PubMed         Abstract available

  22. SUZUKI T, Kita Y, Yanagida K, Maeda K, et al
    Molecular signature of COVID-19 prior to its exacerbation by multi-omics survey.
    PLoS One. 2026;21:e0352423.
    PubMed         Abstract available

  23. ELLIS K, Hall P, Robinson L, Ruiz S, et al
    COVID-19 vaccine confidence among adults of pima county using the NIMHD minority health and health disparities research framework: A qualitative analysis.
    PLoS One. 2026;21:e0353345.
    PubMed         Abstract available

  24. HIRSCH JA, Besser LM, Pescador Jimenez M, Dickinson ST, et al
    Spatial and neighborhood data in the collaborative cohort of cohorts for COVID-19 Research (C4R).
    PLoS One. 2026;21:e0352170.
    PubMed         Abstract available

  25. LA EM, Gallington K, Singer D, Fikre T, et al
    US healthcare professionals' knowledge, attitudes, and practices regarding RSV disease and vaccination in adults during the 2024-2025 RSV season.
    PLoS One. 2026;21:e0353266.
    PubMed         Abstract available

  26. HAMUNAKWADI DL, Smith SL
    The news media and the agenda for noncommunicable diseases before and during the COVID-19 pandemic: Losing the competition for coverage and framing responsibility for action in Malawi.
    PLoS One. 2026;21:e0341285.
    PubMed         Abstract available

  27. IBRAHIM S, Yakubu Y, Appiagyei K, Sylvester AFD, et al
    Factors associated with severe acute respiratory syndrome coronavirus-2 infection in Hohoe Municipality, Ghana: A case-control study.
    PLoS One. 2026;21:e0332561.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  28. MISTRY HB
    Hazard curvature makes within-host variability costly for survival.
    Proc Natl Acad Sci U S A. 2026;123:e2610568123.
    PubMed         Abstract available


    Vaccine

  29. OKOLI GN, Sullivan SG, Harper DM, Tsang TK, et al
    A systematic meta-analytic comparative evaluation of seasonal influenza vaccine effectiveness from test-negative design studies in the Northern Hemisphere pre/post COVID-19 pandemic.
    Vaccine. 2026;88:128956.
    PubMed         Abstract available

  30. WANG WC, Alhashimi M, Gairola V, Murala MST, et al
    Lung-resident T-cell immunity dominates protection induced by an intranasal adenoviral nucleoprotein influenza vaccine.
    Vaccine. 2026;88:128962.
    PubMed         Abstract available


    Virology

  31. YOSHIDA K, Yamamoto S, Ogasawara N, Taniguchi K, et al
    Innate immune-regulated sulfated glycosaminoglycans are associated with progeny respiratory syncytial virus retention at the cell surface in immortalized cell lines.
    Virology. 2026;623:110974.
    PubMed         Abstract available

  32. DICKERSON A, Cruceanu A, Pokharel BR, Majumdar N, et al
    Deciphering the miR-29c-3p / TET3 regulatory axis within the SARS-CoV-2-infected midbrain.
    Virology. 2026;623:110989.
    PubMed         Abstract available

  33. WANG Z, Pan Q, Arduini A, Liang C, et al
    Identification of SARS-CoV-2 proteins suppressing host protein synthesis.
    Virology. 2026;623:111006.
    PubMed         Abstract available

  34. MANDVIWALA AS, Liman K, Huckriede ALW, Mishra AC, et al
    Evaluation of MPLA and chimeric TLR agonist adjuvants in RSV virus-like particle vaccines delivered by the intramuscular route.
    Virology. 2026;623:111007.
    PubMed         Abstract available

  35. ABDEL-MONEIM AS, Al-Balushi MS, Al-Jabri AA
    Post-COVID-19 immune dysregulation and autoimmune sequelae.
    Virology. 2026;623:111017.
    PubMed         Abstract available


    Virus Res

  36. TANG Y, Gao X, Ding H, Kong L, et al
    Biological Aging, Immune Phenotypes, and Susceptibility to COVID-19 and Sepsis: A Mendelian Randomization Study.
    Virus Res. 2026;370:199756.
    PubMed         Abstract available

Sunday, July 19, 2026

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, July 19 '26)

 


    BMC Pediatr

  1. CHOO MY, Lum LCS, Jalal MIA, Ooi KS, et al
    Nutritional disparities between urban poor and non-poor Malaysian children under five in the context of the COVID-19 pandemic: a cross-sectional study.
    BMC Pediatr. 2026 Jun 5. doi: 10.1186/s12887-026-07079.
    PubMed         Abstract available

  2. KENDRIC KJ, Durrani TS
    Trends in pediatric household cleaning product exposures before and during the COVID-19 pandemic: a national poison data system analysis (2016-2023).
    BMC Pediatr. 2026;26:658.
    PubMed         Abstract available


    Epidemiol Infect

  3. AMEMIYA Y, Nishiura H
    Using forensic autopsy data to estimate the age-specific infection fatality risk of COVID-19.
    Epidemiol Infect. 2026;154:e96.
    PubMed         Abstract available

  4. MCGEOCH L, Stoker K, Rome M, Carey C, et al
    What is the burden of respiratory syncytial virus outbreaks in care homes? An enhanced surveillance study in England, winter 2024/25.
    Epidemiol Infect. 2026;154:e99.
    PubMed         Abstract available


    J Epidemiol Community Health

  5. WING K, Morton C, Mahalingasivam V, Costello RE, et al
    Occurrence and persistence of symptoms, diagnoses and prescriptions after community-diagnosed COVID-19: a matched cohort study using the OpenSAFELY platform.
    J Epidemiol Community Health. 2026;80:624-634.
    PubMed         Abstract available


    J Infect Dis

  6. FLANNERY B, Chung JR, Holiday C, Jefferson S, et al
    Influenza Antibody Levels Associated with Laboratory-Confirmed Influenza in a Test-Negative Study Design, US Flu VE Network, November 2018-May 2019.
    J Infect Dis. 2026 Jul 17:jiag371. doi: 10.1093.
    PubMed         Abstract available

  7. KAWAI N, Bando T, Kawashima T, Matsuura S, et al
    Influenza Attack Rates and Vaccine Effectiveness by Prior-Season Infection and Vaccination: A 17-Season Analysis.
    J Infect Dis. 2026 Jul 11:jiag352. doi: 10.1093.
    PubMed         Abstract available

  8. ROGERS S, Sumner KM, Yang Y, Johnson E, et al
    Protective effects of influenza B neuraminidase antibodies against symptomatic influenza virus infection.
    J Infect Dis. 2026 Jul 10:jiag351. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  9. CIMINSKI K, Reuther P, Rijkers R, de Vries RP, et al
    The receptor landscape of influenza A viruses.
    J Virol. 2026 Jul 16:e0144325. doi: 10.1128/jvi.01443.
    PubMed         Abstract available

  10. SHIRAZI R, Kim SY, Cruz A, Stumpff JP, et al
    RELMalpha establishes a permissive environment for influenza virus infection through direct effects on lung epithelial cells.
    J Virol. 2026 Jul 16:e0222525. doi: 10.1128/jvi.02225.
    PubMed         Abstract available


    Lancet

  11. BLAKNEY AK, Top KA, Cowling BJ, Larson HJ, et al
    Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.
    Lancet. 2026 Jun 30:S0140-6736(26)00512-X. doi: 10.1016/S0140-6736(26)00512.
    PubMed         Abstract available


    PLoS Comput Biol

  12. DA SILVA K, Naffakh N, Rameix-Welti MA, Lemoine F, et al
    Accounting for Defective Viral Genomes in viral consensus genome reconstruction, application to influenza virus.
    PLoS Comput Biol. 2026;22:e1014115.
    PubMed         Abstract available


    PLoS One

  13. OKUI T
    Difference in excess mortality during the COVID-19 pandemic depending on marital status in Japan.
    PLoS One. 2026;21:e0354263.
    PubMed         Abstract available

  14. KARIM A, Al Mamun MA, Sultana S, Kabilan MK, et al
    Teaching persuasive essay writing online to first-year undergraduates: A phenomenological study of instructional design and learning experiences.
    PLoS One. 2026;21:e0353171.
    PubMed         Abstract available

  15. MICHEL S, Kempf C, Pirschtat N, Herbstreit F, et al
    Herpesvirus reactivation is associated with mortality in critically ill ICU patients with COVID-19: Insights from a retrospective single-center analysis of 455 cases.
    PLoS One. 2026;21:e0354153.
    PubMed         Abstract available

  16. MA C, Sun J, Liu Z, Zhang C, et al
    Skin manifestations of primary COVID-19 infection with the omicron variant.
    PLoS One. 2026;21:e0352201.
    PubMed         Abstract available

  17. MADDEN D
    Covid-19 related excess mortality: An analysis by age for selected countries.
    PLoS One. 2026;21:e0353766.
    PubMed         Abstract available

  18. BOMANS S, Michotte N, El M'Rabet I, Jimenez Garcia B, et al
    Agreement and reliability between the two-day 6-minute incremental step test and two-day cardiopulmonary exercise test in post COVID-19 condition for assessing post-exertional malaise: The REVEAL-study.
    PLoS One. 2026;21:e0353132.
    PubMed         Abstract available

  19. CAPODICI A, Filippeschi A, Noci F, Michelucci A, et al
    Mapping global inequities in telemedicine implementation: An umbrella review of barriers and facilitators.
    PLoS One. 2026;21:e0351885.
    PubMed         Abstract available

  20. WIELAND V, Wassmuth N, Contento L, Kuhn M, et al
    Assessment of simulation-based inference methods for stochastic compartmental models in epidemiological research.
    PLoS One. 2026;21:e0353306.
    PubMed         Abstract available

  21. DILILLO KM, Forconi CS, Matta A, Melo J, et al
    Estimating SARS-CoV-2 exposure in asymptomatic hospitalized children with cancer in Western Kenya: A retrospective analysis of serological data.
    PLoS One. 2026;21:e0353284.
    PubMed         Abstract available

  22. ROBINSON B, Bisaillon P, Sandhu R, Khalil M, et al
    Semi-analytical hierarchical Bayesian inference of nonlinear model structure in stochastic dynamics: Applied to compartmental models of infectious diseases.
    PLoS One. 2026;21:e0350747.
    PubMed         Abstract available

  23. ROSYCHUK RJ, Lee BE, Qiu JY, Gao T, et al
    Exploring the predictability of distributed lag nonlinear models using SARS-CoV-2 wastewater-based surveillance in multiple communities in Alberta, Canada.
    PLoS One. 2026;21:e0349030.
    PubMed         Abstract available

  24. KAYUMBA K, Duga A, Papa Fallah M, Tshidibi C, et al
    Adverse events following immunization during COVID-19 mass vaccination campaigns in the Democratic Republic of Congo: Findings from active safety surveillance.
    PLoS One. 2026;21:e0309628.
    PubMed         Abstract available


    Vaccine

  25. TU T, Tseng CY, Islam MD, Hsu WL, et al
    Adjuvant-free pH-controlled aggregates of E. coli-expressed H1N1-RBD enhance neutralizing antibody responses and confer protection against influenza virus.
    Vaccine. 2026;88:128898.
    PubMed         Abstract available

  26. GROOTENDORST A, Paludan-Muller AS, Madsen K, Stovring H, et al
    Expanding enhanced influenza vaccines programs for adults aged >/=65 in the Nordic region predicted to improve public health and health system resilience.
    Vaccine. 2026;88:128934.
    PubMed         Abstract available

Saturday, July 11, 2026

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, July 11 '26)

 


    BMC Pediatr

  1. HEIBA D, Salem N, Antonios M, Shoman W, et al
    Comparative study of post- COVID-19 Kawasaki disease and multisystem inflammatory syndrome cases at Alexandria University Children's Hospital.
    BMC Pediatr. 2026;26:644.
    PubMed         Abstract available

  2. LIN C, Zhu Z, Li Y, Wei J, et al
    Diagnostic value of cytokine detection in children with Mycoplasma pneumoniae pneumonia complicated by bacterial or viral co-infections.
    BMC Pediatr. 2026;26:629.
    PubMed         Abstract available


    Epidemiol Infect

  3. DAVOODI Z, Laurie C, Tingley K, Skidmore B, et al
    Risk-of-bias assessment of vaccine effectiveness studies: a scoping review of systematic reviews.
    Epidemiol Infect. 2026;154:e95.
    PubMed         Abstract available

  4. ROSCA EC, Oke J, Jefferson T, Brassey J, et al
    Serial cycle threshold to assess the infectious potential of SARS-CoV-2: A systematic review.
    Epidemiol Infect. 2026;154:e89.
    PubMed         Abstract available


    J Clin Microbiol

  5. MCTAGGART LR, Eshaghi A, Cronin K, Patel SN, et al
    Post-pandemic surge of Mycoplasma pneumoniae in Ontario, 2024: molecular surveillance and resistance trends relative to 2018-2023.
    J Clin Microbiol. 2026;64:e0018826.
    PubMed         Abstract available


    J Infect

  6. LI Y, Zhang T, Gao J
    Home-Based Rapid Testing and Early Antiviral Treatment as a Potential Strategy to Blunt Pediatric Influenza Peak.
    J Infect. 2026 Jul 7:106807. doi: 10.1016/j.jinf.2026.106807.
    PubMed        


    J Infect Dis

  7. SKELLINGTON CN, Schmidt K, Schofield C, Ganesan A, et al
    The Effect of Prevaccination Analgesics on Influenza Vaccine Immunogenicity and Effectiveness.
    J Infect Dis. 2026 Jul 10:jiag334. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  8. JIA H, Lin C, Guo Y, Cai W, et al
    A neuraminidase-targeted nanobody confers broad protection against influenza B virus.
    J Virol. 2026 Jul 10:e0076226. doi: 10.1128/jvi.00762.
    PubMed         Abstract available

  9. BARRON-CASTILLO U, Berube N, Swan CL, Javed MA, et al
    Receptor profiling and growth assessment of influenza A virus in porcine mammary and non-mammary tissues and derived cells.
    J Virol. 2026 Jul 6:e0061526. doi: 10.1128/jvi.00615.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  10. PATRICK R, Lee K, Kuan M, Chan M, et al
    Norovirus, COVID-19, and Influenza Outbreaks Among Residents and Staff Members at the Eaton Wildfire Evacuation Shelter - Pasadena, California, January-February 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:337-342.
    PubMed         Abstract available


    Pediatrics

  11. LEONARD JS, Reinhart K, Lu PJ, Santibanez TA, et al
    Influenza Vaccine Effectiveness Against Pediatric Death in the United States: 2016-2025.
    Pediatrics. 2026 Jul 6:e2026076453. doi: 10.1542/peds.2026-076453.
    PubMed         Abstract available

  12. HAHN C, Sardi A, Ratner AJ
    Averting the Unthinkable: Immunization to Prevent Childhood Deaths From Influenza.
    Pediatrics. 2026 Jul 6:e2026076867. doi: 10.1542/peds.2026-076867.
    PubMed        


    PLoS Comput Biol

  13. WANG B, Valdano E
    Redefining and estimating the early-phase reproduction ratio for epidemic outbreaks in spatially structured populations.
    PLoS Comput Biol. 2026;22:e1014425.
    PubMed         Abstract available


    PLoS One

  14. LI W, Tan HL, Zhuang CY, Li JY, et al
    Parental knowledge, vaccine hesitancy, and practices regarding seasonal influenza vaccination for preschool-aged children in Shenzhen, China: Insights from a cross-sectional survey.
    PLoS One. 2026;21:e0353478.
    PubMed         Abstract available

  15. SANOGO IN, Puryear WB, Simulynas AF, DiGiovanni R, et al
    Serological evidence of SARS-CoV-2 exposure in marine mammals in the United States between 2020 and 2025.
    PLoS One. 2026;21:e0351734.
    PubMed         Abstract available

  16. HIRATA K, Chiba T, Takaku R, Meilai C, et al
    Beyond the freedom to refuse patient: A retrospective comparative study of emergency transportation during the COVID-19 pandemic in Japan.
    PLoS One. 2026;21:e0331535.
    PubMed         Abstract available

  17. HAKKI S, Nevin S, Conibear E, Madon KJ, et al
    Full blood count dynamics in immunologically naive individuals with mild COVID-19: A prospective community cohort study.
    PLoS One. 2026;21:e0353142.
    PubMed         Abstract available

  18. BURCHARDI JM, Brunger M, Freitag H, Brock A, et al
    Improving the care of people affected by post-COVID syndrome (LCovB):study protocol of a mixed-methods study.
    PLoS One. 2026;21:e0353270.
    PubMed         Abstract available

  19. AL-AGHBARI N
    Serum albumin and blood urea as independent predictors of in-hospital mortality in hospitalized COVID-19 patients: A retrospective cohort study.
    PLoS One. 2026;21:e0353456.
    PubMed         Abstract available

  20. JEWELL M, Marye A, Barbeau B, Oakeson K, et al
    Beyond traditional outbreak investigation: Using genomic data for enhanced detection of COVID-19 disease clusters in Utah.
    PLoS One. 2026;21:e0342637.
    PubMed         Abstract available

  21. IIDA K, Mori H, Remez D, Krokva D, et al
    Epidemiological characteristics of amebiasis in Japan from 2001 to 2022.
    PLoS One. 2026;21:e0318901.
    PubMed         Abstract available

  22. FREDERIKSEN L, Subedi S, Choong K, Anderson J, et al
    Respiratory and bloodstream coinfections and antimicrobial use in hospitalised patients with moderate to severe COVID-19: An Australian retrospective cohort study.
    PLoS One. 2026;21:e0352344.
    PubMed         Abstract available

  23. FUKUDA T, Haruyama R, Tanaka Y, Natori S, et al
    Development of a COVID-19 Vaccination Anxiety Scale to measure COVID-19 vaccine anxiety in Japanese adults.
    PLoS One. 2026;21:e0330146.
    PubMed         Abstract available

  24. MICHALAKI E, Van Zanten A, Najjar J, Byagathvalli G, et al
    A piezoelectric electroporator (Piezopen) for enhanced "naked" RNA vaccine delivery.
    PLoS One. 2026;21:e0353214.
    PubMed         Abstract available

  25. GACH D, van Osch FHM, van den Bergh JP, Posthuma R, et al
    Long-term multidimensional health status of individuals with and without post COVID-19 condition: A cross-sectional study.
    PLoS One. 2026;21:e0352332.
    PubMed         Abstract available

  26. CONGDON C, Malik F, Jina R, Kumar D, et al
    A multi-country qualitative evaluation of rapid mortality surveillance during the COVID-19 pandemic.
    PLoS One. 2026;21:e0333157.
    PubMed         Abstract available


    Vaccine

  27. ZHANG L, Lin T, Wang M, Ma X, et al
    Retraction notice to "Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial" [Vaccine 82 (2026) 128588].
    Vaccine. 2026 Jul 6:128885. doi: 10.1016/j.vaccine.2026.128885.
    PubMed        

My New Space

Most Popular Posts